Diasome Pharmaceuticals, Inc. is developing hepatocyte directed vesicle (HDV) technology, an insulin additive, to lessen the instances of high and low blood sugar levels in people with diabetes to improve disease management and quality of life. HDV may improve the safety and efficacy of any commercially available insulin by restoring the liver’s natural role in blood glucose control.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.